Nicole LaBrosse sold $174k of HALO
SVP, CHIEF FINANCIAL OFFICER at HALOZYME THERAPEUTICS, INC.. 2,227 shares at an average of $77.95, traded Sep 22, 2025, filed Sep 23, 2025.
Score components
- +22RoleCFO
- +11Trade size$174k at market
- 0Share of holdings soldSold 9.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.8%, 3m -11.9%, 6m -20.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001910662-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 22, 2025 | SOpen-market sale Common Stock10b5-1 | -1,913 | $77.83 | $149k | 22,393 | Sep 23, 2025 |
| Sep 22, 2025 | SOpen-market sale Common Stock10b5-1 | -314 | $78.67 | $25k | 22,079 | Sep 23, 2025 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.3M 60,000 shares | -8% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $167k 1,626 shares | -4% | |
| 16Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $153k 1,923 shares | -0% | |
| 20Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $125k 1,625 shares | -4% | |
| 24Weak | HALOZYME THERAPEUTICS, INC. | Mahesh Krishnan director | $548k 7,304 shares | -34% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.4M 50,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.